NeuroMetrix: Encouraging Trial Results in Chemotherapy Induced Peripheral Neuropathy

 NeuroMetrix, Inc.,  (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN): A proof-of-concept, placebo-controlled, randomized clinical trial (RCT)." The abstract will be published at the 2023 American Society of Clinical Oncology (ASCO) annual meeting to take place June 2-6 in Chicago, IL. The principal investigator is Dr. Jennifer Gewandter of the University of Rochester School of Medicine and Dentistry. The trial leveraged the National Cancer Institute (NCI) Community Oncology Research Program (NCORP).

The study was a phase II, multi-site, double blinded, randomized, sham-controlled trial. A total of 142 subjects with CIPN were randomized to an active or sham Quell device for 6-weeks. Subjects in both arms were instructed to wear their device for 5 hours each day. As reported in the abstract, patients with moderate to severe CIPN symptoms of hot/burning pain, sharp/shooting pain or muscle cramping experienced about a 50% reduction in symptoms for active treatment compared to about 30% for sham treatment. The study authors concluded "A RCT of an app-controlled, wireless TENS device for chronic CIPN with excellent adherence and retention rates is feasible in NCORP. Preliminary efficacy evidence suggests that TENS [Quell] is promising for pain and cramping from CIPN ... A confirmatory RCT of TENS for painful CIPN is highly warranted." The abstract is available at link and the study details are available at NCT04367480.

https://www.biospace.com/article/releases/quell-demonstrates-encouraging-clinical-trial-results-in-chemotherapy-induced-peripheral-neuropathy-cipn-/